Marker Therapeutics Inc (MRKR)

[microcapbiotech]

The FDA has granted "accelerated approval" for Talvey (Johnson & Johnson/Janssen), a new antibody-based therapy for adult patients with tough-to-treat blood cancers such as multiple myeloma. It has a Boxed Warning for life threatening or fatal cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity (ICANS).

Here's an idea, how about the FDA give Multi-TAA "accelerated approval" for AML as it does NOT create life threatening or fatal cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity (ICANS).